However, the clear difference in FL-SMN/SMNΔ7 mRNA ratio between SMA patients and normal individuals, as found in this study and also shown by others, suggests the usefulness of this biomarker for detecting changes during SMA pharmacotherapy. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.